Exton’s Immunome Awarded Department of Defense Contract to Develop Biosynthetic Convalescent Plasma for COVID-19


EXTON, PAImmunome, a biotechnology company that harnesses the human B cell response to develop first-in-class therapeutics for oncology and infectious diseases, recently announced it has been awarded up to $13.3M from the U.S. Department of Defense (DoD) to use its proprietary technology to develop a novel biosynthetic convalescent plasma (BCP) as a new potential approach to combat the COVID-19 pandemic.

Immunome’s technology works with breadth, depth and speed to interrogate B cells from patients who have successfully recovered from the COVID-19 infection. Through this effort, Immunome intends to identify a combination of antibodies that are broadly active against the virus, enable multiple viral clearance mechanisms and will be synthetically manufactured for availability to broad patient populations.

Immunome’s scientific founder, Dr. Scott Dessain, MD, PhD, and his colleagues have validated this technology platform by successfully identifying broadly neutralizing antibodies against various strains of the poliovirus1,2,3. In addition to using this technology to prevent and treat COVID-19, the company is in pre-clinical testing of antibody-based therapeutics against multiple novel oncology targets.

READ:  Commonwealth Encourages Older Adults to Reach Out if COVID-19 Vaccine Appointment Assistance Is Needed

“With this endeavor, Immunome is harnessing its foundational B cell biology and antibody expertise towards COVID-19 research. We are thankful to the DoD, in collaboration with the Joint Program Executive Office for Chemical, Biological, Radiologial and Nuclear Defense (JPEO-CBRND) and its Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical (JPM CBRN Medical), for understanding and recognizing the potential of Immunome’s therapeutic antibody discovery engine in the development of a new treatment against the deadly SARS-CoV-2 virus,” said Purnanand Sarma, PhD, president and CEO of Immunome.

“Our proprietary technology is designed to rapidly evaluate the broad immune response of patients who have recovered from COVID-19 by generating up to 10,000 B cell hybridomas from each patient. By doing this in a completely unbiased manner, we aim to isolate the most potent antibodies against this viral threat. If successful, this approach may be used for both treatment and prophylaxis.”

Convalescent plasma, which is derived from patients who have recovered from a disease, has been used to treat patients during the 1918 flu pandemic and more recently to fight severe cases of the flu, MERS, SARS, and even COVID-19. While promising, convalescent plasma has limitations, such as availability of donor plasma at large scale, donor-to-donor variability related to their individual response, and time of collection. Immunome’s approach is designed to overcome these challenges and provide an industrially scalable, standardized process for development and manufacturing of a BCP alternative to convalescent plasma that may comprise 4-6 highly potent anti SARS-CoV-2 antibodies.

READ:  April 12 COVID-19 Update: 311,995 Vaccinations to Date in Chester County

“Antibody-rich plasma from COVID-19 survivors is emerging as a successful treatment for newly infected patients,” said infectious diseases specialist Dr. Jeffrey Henderson, MD, PhD, an associate professor of medicine at Washington University School of Medicine in St. Louis and a member of the National COVID-19 Convalescent Plasma Project (www.ccpp19.org).

“These results suggest that Immunome’s approach of reproducing the multi-faceted antibody response of COVID-19 survivors could be particularly effective in treating patients, or possibly as a preventive. The consistency and scale of lab-produced antibodies also may help more rapidly facilitate the supply of antibodies available for clinical use.”

The DoD’s JPEO-CBRND, and its subordinate JPM CBRN Medical, provide medical countermeasures for the warfighter and the nation against biological and chemical agents of concern. This award draws on that expertise to respond to the COVID-19 outbreak.

READ:  April 12 COVID-19 Update: 319,133 Vaccinations to Date in Chester County

Immunome’s technology may also have applicability beyond COVID-19, as it can also be used as a rapid response technology to quickly develop treatments during future outbreaks from other infectious agents.

1Vaccine, 35:5455-5462; 2017 (doi: 10.1016/j.vaccine.2017.03.038.)
2 J Virol Methods. 276:113785 (doi: 10.1016/j.jviromet.2019.113785)
3 Antibodies, 9; 2020 (doi.org/10.3390/antib9010005

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee